For many cell-based vaccines, the precursor monocytes or CD34+ cells are cultured with cytokines to obtain dendritic cells, which are very potent antigen-presenting cells (APCs).
Lee K. Roberts
Advertisement
Articles by Lee K. Roberts
Advertisement
Latest Updated Articles
Cancer Vaccines: Asymptotically Approaching Product ApprovalPublished: August 2nd 2007 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
2
Biotech Equipment Market to Approach $144B by 2030: Implications for Pharma R&D
3
Everything to Know About Cell and Gene Therapy in 2025
4
Strategies for Building Tech Talent in the Biopharma Industry (Part 4)
5
